

# In vivo relationship of interleukin-2 and soluble IL-2 receptor impairment in patients with active multiple sclerosis

Journal of Neurology

240, 46-50

DOI: [10.1007/bf00838446](https://doi.org/10.1007/bf00838446)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Correlation of interleukin-2 and soluble interleukin-2 receptor with clinical activity of multiple sclerosis.. Journal of Neurology, Neurosurgery and Psychiatry, 1993, 56, 169-174.	0.9	54
3	The pathogenesis of demyelinating disease. Progress in Neurobiology, 1994, 43, 143-173.	2.8	53
4	The blood-brain barrier and multiple sclerosis. Biochemical Pharmacology, 1994, 47, 1717-1724.	2.0	45
5	Multiple sclerosis: Immune mechanism and update on current therapies. Annals of Neurology, 1995, 37, 87-101.	2.8	44
6	Cerebrospinal fluid and serum from patients with inflammatory polyradiculoneuropathy have opposite effects on sodium channels. Muscle and Nerve, 1995, 18, 772-781.	1.0	29
7	Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. Journal of Neurology, 1995, 242, 53-58.	1.8	29
8	A Co-evolutionary theory of sleep. Medical Hypotheses, 1995, 45, 304-310.	0.8	12
9	Excitatory sodium currents of NH15-CA2 neuroblastoma x glioma hybrid cells are differently affected by interleukin-2 and interleukin-1 $\beta$ . Pflugers Archiv European Journal of Physiology, 1996, 433, 160-165.	1.3	8
10	Patterns of disease activity in multiple sclerosis patients: A study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups. Journal of Neurology, 1996, 243, 536-542.	1.8	37
11	Time-course of interleukin-2 receptor expression in interferon beta-treated multiple sclerosis patients. Journal of Neuroimmunology, 1998, 84, 213-217.	1.1	8
12	Multiple Sclerosis: IL-2 and sIL-2R levels in cerebrospinal fluid and serum. Review of literature and critical analysis of ELISA pitfalls. Multiple Sclerosis Journal, 1998, 4, 7-11.	1.4	19
13	Interleukin-2 and Its Effects in the Central Nervous System. NeuroSignals, 1998, 7, 148-156.	0.5	35
14	Tumour necrosis factor- $\alpha$ has few morphological effects within the dorsal columns of the spinal cord, in contrast to its effects in the peripheral nervous system. Journal of Neuroimmunology, 2000, 106, 130-136.	1.1	23
15	Elevated Serum Titers of Proinflammatory Cytokines and CNS Autoantibodies in Patients with Chronic Spinal Cord Injury. Journal of Neurotrauma, 2002, 19, 753-761.	1.7	185
16	Endothelial Cells and Adhesion Molecules in Experimental Autoimmune Encephalomyelitis. , 2005, , 151-179.		0
17	Dopaminergic Modulation of CD4+CD25 <sup>high</sup> Regulatory T Lymphocytes in Multiple Sclerosis Patients during Interferon- $\gamma$ Therapy. NeurolImmunoModulation, 2012, 19, 283-292.	0.9	43
18	Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics. BMC Medicine, 2013, 11, 205.	2.3	121
20	Effect of Pramipexole on Inflammatory Response in Central Nervous System of Parkinson's Disease Rat Model. Archives of Medical Research, 2022, 53, 37-43.	1.5	4

#	ARTICLE	IF	CITATIONS
21	Cytokines in multiple sclerosis cerebrospinal fluid and serum. , 1996, , 93-104.		2
22	Differences in ABCA1 R219K Polymorphisms and Serum Indexes in Alzheimer and Parkinson Diseases in Northern China. Medical Science Monitor, 2017, 23, 4591-4600.	0.5	16
24	Cytokine abnormalities in schizophrenia: a review of their pathogenic significance, with particular reference to the autoimmune hypothesis. Key Topics in Brain Research, 1997, , 39-49.	0.2	0